The BATF3 Knockout 143B Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human 143B osteosarcoma line, providing a loss-of-function model for BATF3. The polyclonal format comprises a heterogeneous pool of cells with targeted disruption of BATF3, ensuring broad representativeness and minimizing clone-specific artifacts for consistent downstream applications.
The 143B line is a highly metastatic human osteosarcoma model, derived from the HOS cell line, that forms tumors in vivo and recapitulates osteolytic bone destruction and pulmonary metastasis. 143B cells are characterized by rapid growth, highly invasive behavior, and the capacity to metastasize robustly to the lungs in orthotopic models, making them a mainstay for preclinical osteosarcoma research. This clinically relevant background allows for rigorous investigation of gene function in tumor progression and metastasis.
BATF3 is a basic leucine zipper transcription factor that heterodimerizes with JUN and cooperates with IRF8 to drive the development of conventional type 1 dendritic cells (cDC1), which are essential for cross-presentation of antigens to CD8+ T cells and anti-tumor immunity. Upstream regulators such as PU.1, GM-CSF, Flt3L, and TLR ligands activate BATF3 expression, while downstream targets include IL12B, CXCL9, and CXCL10, which promote T cell recruitment and activation. BATF3 interacts with IRF4 and AP-1 complex components, forming a transcriptional network that integrates NF-??B signaling and regulates cross-presentation through effectors like TAP1 and MHC class I.
In the 143B osteosarcoma context, this knockout model enables investigation of BATF3??s potential tumor-intrinsic roles and its influence on the immune microenvironment. Although BATF3 is primarily characterized in dendritic cells, its disruption in a metastatic bone cancer line facilitates studies on altered cytokine secretion, chemokine expression, and immune cell interactions. This system is particularly valuable for dissecting the role of the cDC1 axis in bone metastasis and for testing immunotherapeutic strategies targeting BATF3-dependent pathways.
Applications include xenograft tumor growth and metastasis studies, cytokine and chemokine profiling (e.g., IL-12, CXCL9, CXCL10) by RT-qPCR and ELISA, flow cytometric analysis of immune cell infiltration in tumor models, and western blotting for BATF3 pathway protein expression. The polyclonal knockout population supports controlled comparisons with wild-type 143B cells, enabling rigorous functional studies of BATF3 in osteosarcoma biology and tumor-immune interactions. For further technical information, please contact Ascent Research.
